Symbols / DNLI Stock $19.87 +2.16% Denali Therapeutics Inc.

Healthcare • Biotechnology • United States • NMS
DNLI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ryan J. Watts Ph.D.
Exch · Country NMS · United States
Market Cap 3.15B
Enterprise Value 2.33B
Income -512.54M
Sales —
FCF (ttm) -244.19M
Book/sh 6.49
Cash/sh 5.47
Employees 503
Insider 10d —
IPO Dec 08, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.69
PEG —
P/S —
P/B 3.06
P/C —
EV/EBITDA -4.30
EV/Sales —
Quick Ratio 8.85
Current Ratio 9.16
Debt/Eq 4.17
LT Debt/Eq —
EPS (ttm) -2.97
EPS next Y -2.58
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-02-26
ROA -27.56%
ROE -45.69%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 158.68M
Shs Float 144.36M
Insider Own 9.13%
Instit Own 99.02%
Short Float 10.17%
Short Ratio 7.98
Short Interest 15.28M
52W High 23.77
vs 52W High -16.41%
52W Low 12.58
vs 52W Low 57.95%
Beta 1.10
Impl. Vol. 88.72%
Rel Volume 0.69
Avg Volume 1.70M
Volume 1.17M
Target (mean) $35.64
Tgt Median $37.00
Tgt Low $25.00
Tgt High $42.00
# Analysts 14
Recom Strong_buy
Prev Close $19.45
Price $19.87
Change 2.16%
About

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$35.64
Mean price target
2. Current target
$19.87
Latest analyst target
3. DCF / Fair value
$-27.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.87
Low
$25.00
High
$42.00
Mean
$35.64

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 main Leerink Partners Outperform → Outperform $35
2026-04-07 main Baird Outperform → Outperform $34
2026-03-26 main Morgan Stanley Overweight → Overweight $42
2026-03-26 main Goldman Sachs Buy → Buy $40
2026-03-26 main Stifel Buy → Buy $41
2026-03-26 main Baird Outperform → Outperform $32
2026-03-26 main HC Wainwright & Co. Buy → Buy $42
2026-03-25 main BTIG Buy → Buy $38
2026-03-02 main BTIG Buy → Buy $36
2026-02-24 init Wolfe Research — → Peer Perform —
2026-02-06 reit BTIG Buy → Buy $32
2025-12-11 main Wedbush Outperform → Outperform $30
2025-12-05 main Wedbush Outperform → Outperform $31
2025-12-05 reit BTIG Buy → Buy $32
2025-11-04 main JP Morgan Overweight → Overweight $26
2025-09-08 reit Cantor Fitzgerald Overweight → Overweight —
2025-08-18 main Morgan Stanley Overweight → Overweight $30
2025-05-19 main B of A Securities Buy → Buy $27
2025-05-08 main Baird Outperform → Outperform $29
2025-05-07 main Wedbush Outperform → Outperform $30
News
RSS: Latest DNLI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-06 WATTS RYAN J Chief Executive Officer — 35,198 $16.50 $580,767
2026-01-06 SCHUTH ALEXANDER O Chief Financial Officer — 17,218 $16.50 $284,097
2026-01-02 WATTS RYAN J Chief Executive Officer — 78,960 $0.00 $0
2026-01-02 SCHUTH ALEXANDER O Chief Operating Officer — 57,700 $0.00 $0
2025-11-04 VAN HAUWERMEIREN TIMOTHY Director — 10,632 $0.00 $0
2025-09-03 WATTS RYAN J Chief Executive Officer — 50,000 $0.00 $0
2025-08-13 HO CAROLE Officer — 3,743 $13.58 $51,684
2025-08-12 SCHUTH ALEXANDER O Chief Financial Officer — 2,937 $13.58 $39,884
2025-08-05 HO CAROLE Officer — 44,655 $0.68 $30,365
2025-07-09 WATTS RYAN J Chief Executive Officer — 495,282 $15.00 $7,429,230
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
330.53
+204.74%
108.46
Operating Revenue
0.00
0.00
-100.00%
330.53
+214.60%
105.06
Operating Expense
555.34
+10.65%
501.88
-4.81%
527.23
+17.37%
449.21
Research And Development
418.78
+5.63%
396.44
-6.47%
423.88
+18.16%
358.73
Selling General And Administration
136.56
+29.52%
105.44
+2.02%
103.35
+14.23%
90.47
General And Administrative Expense
136.56
+29.52%
105.44
+2.02%
103.35
+14.23%
90.47
Other Gand A
136.56
+29.52%
105.44
+2.02%
103.35
+14.23%
90.47
Total Expenses
555.34
+10.65%
501.88
-4.81%
527.23
+17.37%
449.21
Operating Income
-555.34
-10.65%
-501.88
-155.15%
-196.70
+42.27%
-340.74
Total Operating Income As Reported
-555.34
-13.95%
-487.34
-147.76%
-196.70
+42.27%
-340.74
EBITDA
-540.53
-9.67%
-492.89
-173.87%
-179.97
+45.52%
-330.36
Normalized EBITDA
-540.53
-6.52%
-507.42
-181.94%
-179.97
+45.52%
-330.36
Reconciled Depreciation
14.81
+64.72%
8.99
-46.24%
16.73
+61.09%
10.38
EBIT
-555.34
-10.65%
-501.88
-155.15%
-196.70
+42.27%
-340.74
Total Unusual Items
0.00
-100.00%
14.54
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
-100.00%
14.54
0.00
0.00
Special Income Charges
0.00
-100.00%
14.54
0.00
0.00
Net Income
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Pretax Income
-512.44
-21.23%
-422.70
-191.13%
-145.19
+55.46%
-325.97
Net Non Operating Interest Income Expense
42.90
-33.62%
64.64
+25.49%
51.51
+248.62%
14.77
Net Interest Income
42.90
-33.62%
64.64
+25.49%
51.51
+248.62%
14.77
Interest Income Non Operating
42.90
-33.62%
64.64
+25.49%
51.51
+248.62%
14.77
Interest Income
42.90
-33.62%
64.64
+25.49%
51.51
+248.62%
14.77
Other Income Expense
—
14.54
—
—
Gain On Sale Of Business
0.00
-100.00%
14.54
0.00
0.00
Tax Provision
0.10
+50.00%
0.07
+126.67%
0.03
+42.86%
0.02
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+20900.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
3.05
0.00
0.00
Net Income Including Noncontrolling Interests
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Net Income From Continuing Operation Net Minority Interest
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Net Income From Continuing And Discontinued Operation
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Net Income Continuous Operations
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Normalized Income
-512.54
-18.03%
-434.26
-199.03%
-145.22
+55.45%
-325.99
Net Income Common Stockholders
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Diluted EPS
—
-2.57
-142.45%
-1.06
+59.23%
-2.60
Basic EPS
—
-2.57
-142.45%
-1.06
+59.23%
-2.60
Basic Average Shares
—
164.47
+19.73%
137.37
+9.43%
125.53
Diluted Average Shares
—
164.47
+19.73%
137.37
+9.43%
125.53
Diluted NI Availto Com Stockholders
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,144.85
-16.69%
1,374.18
+19.09%
1,153.92
-20.98%
1,460.24
Current Assets
900.66
+4.19%
864.44
-18.77%
1,064.14
-22.46%
1,372.32
Cash Cash Equivalents And Short Term Investments
867.88
+4.27%
832.33
-19.54%
1,034.51
-22.58%
1,336.21
Cash And Cash Equivalents
205.33
+17.36%
174.96
+37.65%
127.11
-41.71%
218.04
Other Short Term Investments
662.55
+0.79%
657.37
-27.55%
907.40
-18.85%
1,118.17
Receivables
2.18
+0.28%
2.17
-36.52%
3.42
-63.15%
9.28
Accounts Receivable
2.18
+0.28%
2.17
-36.52%
3.42
-63.15%
9.28
Prepaid Assets
30.60
+2.23%
29.93
+14.23%
26.21
-2.30%
26.82
Other Current Assets
—
—
—
36.10
Total Non Current Assets
244.20
-52.09%
509.74
+467.77%
89.78
+2.11%
87.92
Net PPE
119.94
-4.53%
125.63
+75.37%
71.64
-3.87%
74.52
Gross PPE
182.83
+2.90%
177.67
+51.03%
117.64
+5.28%
111.74
Accumulated Depreciation
-62.90
-20.85%
-52.04
-13.13%
-46.00
-23.61%
-37.22
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.25
+11.28%
3.82
+4.77%
3.65
+14.51%
3.19
Other Properties
130.82
+3.05%
126.95
+74.48%
72.75
+12.18%
64.86
Leases
47.76
+1.81%
46.91
+13.74%
41.24
-5.63%
43.70
Investments And Advances
98.32
-72.64%
359.37
0.00
0.00
Other Investments
—
—
—
—
Other Non Current Assets
25.94
+4.84%
24.74
+36.37%
18.14
+35.41%
13.40
Total Liabilities Net Minority Interest
131.09
-9.28%
144.50
+17.51%
122.96
-70.57%
417.81
Current Liabilities
98.35
-3.77%
102.21
+31.07%
77.98
-78.57%
363.92
Payables And Accrued Expenses
35.52
-30.77%
51.32
+4.45%
49.13
-0.67%
49.46
Payables
3.33
-70.10%
11.14
+17.44%
9.48
+32.11%
7.18
Accounts Payable
3.33
-70.10%
11.14
+17.44%
9.48
+239.89%
2.79
Current Accrued Expenses
32.20
-19.87%
40.18
+1.34%
39.65
-6.24%
42.29
Pensionand Other Post Retirement Benefit Plans Current
32.18
+30.13%
24.73
+14.53%
21.59
+26.35%
17.09
Current Debt And Capital Lease Obligation
9.55
-20.67%
12.03
+65.76%
7.26
-0.79%
7.32
Current Capital Lease Obligation
9.55
-20.67%
12.03
+65.76%
7.26
-0.79%
7.32
Current Deferred Liabilities
21.10
+49.35%
14.13
0.00
-100.00%
290.05
Current Deferred Revenue
—
—
0.00
-100.00%
290.05
Total Non Current Liabilities Net Minority Interest
32.74
-22.57%
42.29
-5.99%
44.98
-16.53%
53.89
Long Term Debt And Capital Lease Obligation
27.21
-25.80%
36.67
-18.47%
44.98
-15.18%
53.03
Long Term Capital Lease Obligation
27.21
-25.80%
36.67
-18.47%
44.98
-15.18%
53.03
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.48
Non Current Deferred Revenue
—
—
0.00
-100.00%
0.48
Other Non Current Liabilities
5.53
-1.48%
5.62
—
0.38
Stockholders Equity
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Common Stock Equity
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Capital Stock
1.89
+6.79%
1.77
+3.33%
1.71
+1.48%
1.69
Common Stock
1.89
+6.79%
1.77
+3.33%
1.71
+1.48%
1.69
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
156.18
+8.29%
144.22
+4.22%
138.39
+1.78%
135.97
Ordinary Shares Number
156.18
+8.29%
144.22
+4.22%
138.39
+1.78%
135.97
Additional Paid In Capital
3,062.72
+10.77%
2,764.88
+28.91%
2,144.81
+6.25%
2,018.62
Retained Earnings
-2,051.52
-33.30%
-1,538.98
-37.88%
-1,116.21
-14.96%
-970.99
Gains Losses Not Affecting Retained Earnings
0.68
-66.24%
2.02
+214.15%
0.64
+109.34%
-6.89
Other Equity Adjustments
0.68
-66.24%
2.02
+214.15%
0.64
+109.34%
-6.89
Total Equity Gross Minority Interest
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Total Capitalization
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Working Capital
802.31
+5.26%
762.23
-22.71%
986.15
-2.21%
1,008.40
Invested Capital
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Total Debt
36.76
-24.54%
48.71
-6.76%
52.24
-13.44%
60.35
Capital Lease Obligations
36.76
-24.54%
48.71
-6.76%
52.24
-13.44%
60.35
Net Tangible Assets
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Tangible Book Value
1,013.76
-17.56%
1,229.68
+19.28%
1,030.95
-1.10%
1,042.43
Available For Sale Securities
—
—
—
—
Duefrom Related Parties Current
—
—
—
0.00
Dueto Related Parties Current
—
—
0.00
-100.00%
4.39
Investmentin Financial Assets
98.32
-72.64%
359.37
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-412.60
-18.67%
-347.69
+2.88%
-357.99
-46.29%
-244.72
Cash Flow From Continuing Operating Activities
-412.60
-18.67%
-347.69
+2.88%
-357.99
-46.29%
-244.72
Net Income From Continuing Operations
-512.54
-21.23%
-422.77
-191.12%
-145.22
+55.45%
-325.99
Depreciation Amortization Depletion
14.81
+64.72%
8.99
-46.24%
16.73
+61.09%
10.38
Depreciation
14.81
+64.72%
8.99
-46.24%
16.73
+61.09%
10.38
Depreciation And Amortization
14.81
+64.72%
8.99
-46.24%
16.73
+61.09%
10.38
Other Non Cash Items
-4.40
-8.03%
-4.07
-9.60%
-3.72
-13.05%
-3.29
Stock Based Compensation
99.63
-3.15%
102.88
-4.83%
108.10
+8.27%
99.85
Operating Gains Losses
—
-14.54
—
—
Change In Working Capital
0.15
-99.12%
16.94
+105.84%
-289.93
-1106.52%
-24.03
Change In Prepaid Assets
-0.54
+78.23%
-2.48
+39.42%
-4.09
-48.33%
-2.76
Change In Payables And Accrued Expense
-7.05
-250.59%
4.68
-7.76%
5.08
-61.50%
13.19
Change In Accrued Expense
0.47
-85.68%
3.25
+22.66%
2.65
-75.75%
10.92
Change In Payable
-7.52
-623.31%
1.44
-40.89%
2.43
+6.90%
2.27
Change In Account Payable
-7.52
-623.31%
1.44
-40.89%
2.43
+6.90%
2.27
Change In Other Working Capital
6.97
-50.65%
14.13
+104.86%
-290.53
-743.05%
-34.46
Change In Other Current Assets
0.77
+28.03%
0.60
0.00
0.00
Change In Other Current Liabilities
0.00
0.00
+100.00%
-0.38
0.00
Investing Cash Flow
255.28
+387.62%
-88.76
-135.60%
249.31
+276.33%
-141.39
Cash Flow From Continuing Investing Activities
255.28
+387.62%
-88.76
-135.60%
249.31
+276.33%
-141.39
Net PPE Purchase And Sale
-9.50
+40.28%
-15.91
-22.98%
-12.94
+27.44%
-17.83
Purchase Of PPE
-9.50
+40.28%
-15.91
-22.98%
-12.94
+27.44%
-17.83
Capital Expenditure
-9.50
+40.28%
-15.91
-22.98%
-12.94
+27.44%
-17.83
Net Investment Purchase And Sale
264.78
+463.49%
-72.84
-127.78%
262.25
+312.25%
-123.55
Purchase Of Investment
-441.26
+64.12%
-1,229.96
+32.18%
-1,813.70
-62.66%
-1,115.04
Sale Of Investment
706.05
-38.98%
1,157.12
-44.26%
2,075.95
+109.38%
991.49
Gain Loss On Sale Of Business
0.00
+100.00%
-14.54
0.00
0.00
Financing Cash Flow
189.22
-60.93%
484.30
+2617.76%
17.82
-94.26%
310.67
Cash Flow From Continuing Financing Activities
189.22
-60.93%
484.30
+2617.76%
17.82
-94.26%
310.67
Net Issuance Payments Of Debt
-8.17
+74.74%
-32.34
0.00
0.00
Repayment Of Debt
-8.17
+74.74%
-32.34
0.00
0.00
Long Term Debt Payments
-8.17
+74.74%
-32.34
0.00
0.00
Net Long Term Debt Issuance
-8.17
+74.74%
-32.34
0.00
0.00
Net Common Stock Issuance
189.25
-62.09%
499.25
0.00
-100.00%
296.21
Proceeds From Stock Option Exercised
8.46
-51.35%
17.39
-2.42%
17.82
+23.28%
14.46
Net Other Financing Charges
-0.32
—
—
—
Changes In Cash
31.90
-33.35%
47.85
+152.67%
-90.86
-20.46%
-75.43
Beginning Cash Position
176.53
+37.19%
128.68
-41.39%
219.54
-25.57%
294.98
End Cash Position
208.43
+18.07%
176.53
+37.19%
128.68
-41.39%
219.54
Free Cash Flow
-422.10
-16.09%
-363.61
+1.97%
-370.93
-41.28%
-262.55
Interest Paid Supplemental Data
0.72
+138.41%
0.30
0.00
—
Income Tax Paid Supplemental Data
0.05
0.00
-100.00%
0.00
-93.62%
0.05
Amortization Of Securities
-10.25
+70.80%
-35.12
+20.10%
-43.95
-2584.91%
-1.64
Common Stock Issuance
189.25
-62.09%
499.25
0.00
-100.00%
296.21
Issuance Of Capital Stock
189.25
-62.09%
499.25
0.00
-100.00%
296.21
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category